FDA panel focus on LST (late-stent thrombosis) is likely to soften DES (drug-eluting stent) penetration of US market
This article was originally published in Clinica
The two-day FDA panel meeting on the safety of drug-eluting stents, which will start tomorrow and end on Friday December 8 (after Clinica's weekly issue, No 1235, goes to press), is the latest chapter in a year of ever-more intense scrutiny of current and prospective players in the $6bn US market DES market.
You may also be interested in...
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.
Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.